Investment Rating - The report maintains an "Outperform" rating for the company [6][4]. Core Insights - The company's core products have seen rapid sales growth after being included in the medical insurance directory, with revenue for the first half of 2025 reaching 1.41 billion yuan, a 37.8% increase year-on-year, and commercial sales revenue of 1.40 billion yuan, up 49.2% [1][9]. - The company reported a loss of 588 million yuan for the first half of 2025, widening from a loss of 249 million yuan in the same period last year, primarily due to investment losses, increased R&D expenses, and stock incentive costs [1][9]. - The company has a strong cash reserve of approximately 7.14 billion yuan as of mid-2025, indicating a solid financial position [1][9]. Summary by Sections Clinical Development - The drug "依沃西" has achieved significant overall survival (OS) benefits in the HARMONi-A trial and has initiated 13 Phase III clinical trials, with 4 trials already showing positive results [2][15]. - Two indications for "依沃西" have been approved in China, and it is also being tested in various cancers, including colorectal and pancreatic cancers [2][15]. Pipeline and Strategy - The company is upgrading its pipeline with a focus on IO2.0 and ADC strategies, with several innovative candidates in clinical trials, including AK137 (CD73/LAG3 dual antibody) and AK138D1 (HER3 ADC) [3][17]. - The company aims to provide new treatment options through internal pipeline combinations [3][17]. Financial Forecast - The report forecasts revenues of 3.30 billion yuan, 5.20 billion yuan, and 7.90 billion yuan for 2025, 2026, and 2027, respectively, with net profits projected at 29 million yuan, 730 million yuan, and 1.79 billion yuan for the same years [4][18].

Group 1 - The Hang Seng Index rose by 0.32% on August 29, closing at 25,077.62 points, with a total net inflow of HKD 12.046 billion through the southbound trading channel [1] - The total trading volume for the southbound trading on August 29 was HKD 180.901 billion, with a net buy of HKD 12.046 billion [1] - In the Shanghai Stock Exchange southbound trading, the total trading volume was HKD 111.266 billion with a net buy of HKD 1.342 billion, while the Shenzhen Stock Exchange had a trading volume of HKD 69.635 billion with a net buy of HKD 10.704 billion [1] Group 2 - The most actively traded stock in the Shanghai Stock Exchange southbound trading was Guotai Junan International, with a trading volume of HKD 53.90 billion, followed by SMIC and Alibaba, with trading volumes of HKD 51.13 billion and HKD 31.39 billion respectively [1] - Tencent Holdings had the highest net buy amount of HKD 620 million, with its stock price increasing by 0.42% [1] - Xiaomi Group had the highest net sell amount of HKD 1.384 billion, with its stock price decreasing by 0.47% [1] Group 3 - In the Shenzhen Stock Exchange southbound trading, Alibaba was the most actively traded stock with a trading volume of HKD 36.02 billion, followed by SMIC and Tencent Holdings with trading volumes of HKD 27.45 billion and HKD 21.56 billion respectively [2] - Tencent Holdings had the highest net buy amount of HKD 964 million, with its stock price increasing by 0.42% [2] - The stock with the highest net sell amount was Changfei Optical Fiber, with a net sell of HKD 179 million, and its stock price decreased by 5.27% [2]

Core Insights - On August 29, Xinhua Insurance made its first appearance on the Hong Kong Stock Connect active trading list in a month, with a trading volume of 2.241 billion HKD and a net sell of 335 million HKD [2][3] - The total trading volume of active stocks on the Hong Kong Stock Connect reached 51.102 billion HKD, accounting for 28.25% of the day's total trading amount, with a net buying amount of 2.774 billion HKD [2] - Among the most actively traded stocks, SMIC led with a trading volume of 7.859 billion HKD, followed by Guotai Junan International and Alibaba-W with trading volumes of 7.251 billion HKD and 6.741 billion HKD, respectively [2] Trading Activity Summary - Xinhua Insurance's trading activity on August 29 included a closing price of 48.14 HKD, reflecting a daily increase of 1.35% [3] - The stocks with the highest trading frequency over the past month included Alibaba-W and Tencent Holdings, each appearing 23 times on the active trading list [2] - Other notable stocks included Xiaomi Group with a trading volume of 4.731 billion HKD and Meituan-W with 4.410 billion HKD, both showing varying daily price changes [2]

Market Overview - On August 29, the Hang Seng Index rose by 0.32%, with southbound trading totaling HKD 180.90 billion, comprising HKD 96.47 billion in buying and HKD 84.43 billion in selling, resulting in a net buying amount of HKD 12.04 billion [1] Southbound Trading Details - Southbound trading through the Stock Connect (Shenzhen) recorded a total transaction amount of HKD 69.63 billion, with buying at HKD 40.17 billion and selling at HKD 29.47 billion, leading to a net buying of HKD 10.70 billion [1] - Southbound trading through the Stock Connect (Shanghai) had a total transaction amount of HKD 111.27 billion, with buying at HKD 56.30 billion and selling at HKD 54.96 billion, resulting in a net buying of HKD 1.34 billion [1] Active Stocks - The most actively traded stock by southbound funds was SMIC, with a total transaction amount of HKD 78.59 billion [1] - Other notable stocks included Guotai Junan International and Alibaba-W, with transaction amounts of HKD 72.51 billion and HKD 67.41 billion, respectively [1] - Tencent Holdings had a net buying amount of HKD 15.84 billion, closing up by 0.42%, while Alibaba-W saw a net buying of HKD 11.49 billion [1][2] Continuous Net Buying - Three stocks experienced continuous net buying for more than three days, with Alibaba-W leading at six consecutive days, followed by Huahong Semiconductor at four days and Kangfang Biotech at three days [2] - The total net buying amounts during this period were HKD 59.75 billion for Alibaba-W, HKD 11.06 billion for Kangfang Biotech, and HKD 9.49 billion for Huahong Semiconductor [2]

Group 1 - The pharmaceutical sector is experiencing a strong rebound, with the Kexin Innovation Drug ETF (589720) rising nearly 5% and seeing continuous net inflows for three consecutive days [1] - The World Lung Cancer Conference (WCLC) and the European Society for Medical Oncology (ESMO) will showcase research results of domestic innovative drugs, including AK112 from Kangfang Biotech and DB-1311 from Ying'en Biotech, in September and October 2025 [1] - The competitiveness of domestic innovative drugs in clinical data and progress is increasing globally, leading to a trend of innovative drugs expanding into international markets [1] Group 2 - The Kexin Innovation Drug ETF (589720) focuses on innovative drug companies listed on the Sci-Tech Innovation Board, tracking a representative index of 30 high-quality companies, primarily in the biotech sector [1] - Since the "924 market" rally, the Kexin Innovation Drug Index has outperformed major Hong Kong innovative drug indices, with respective gains of 75%, 70%, and 70% during the market rebound period from September 24, 2024, to June 30, 2025 [1] - The Kexin Innovation Drug Index may provide better exposure to the resilience of the Sci-Tech Innovation Board when market risk appetite increases [1]

Group 1 - On August 29, 2025, Guotai Junan International (01788), SMIC (00981), and Alibaba-W (09988) were the top three companies by trading volume in the Southbound Stock Connect, with trading amounts of 5.39 billion, 5.11 billion, and 3.14 billion respectively [1] - In the Southbound Stock Connect for Shenzhen-Hong Kong, Alibaba-W (09988), SMIC (00981), and Tencent Holdings (00700) led the trading volume, with amounts of 3.60 billion, 2.75 billion, and 2.16 billion respectively [1] Group 2 - The top ten active companies in the Southbound Stock Connect (Shanghai-Hong Kong) included Guotai Junan International (01788) with a net buy of 0.18 billion, SMIC (00981) with a net sell of 0.46 billion, and Alibaba-W (09988) with a net buy of 0.25 billion [2] - In the Southbound Stock Connect (Shenzhen-Hong Kong), Alibaba-W (09988) had a net buy of 0.90 billion, SMIC (00981) had a net buy of 0.39 billion, and Tencent Holdings (00700) had a net buy of 0.96 billion [2]

Investment Rating - The report maintains a "Buy" rating for Ctrip and Mxue Group, while upgrading Mxue Group's rating from "Hold" to "Buy" [2][8]. Core Insights - Ctrip's Q2 2025 revenue grew by 16% year-on-year to 14.9 billion yuan, with a non-GAAP operating profit of 4.7 billion yuan and a non-GAAP operating margin of 31%, exceeding expectations due to lower marketing expenses [2][7]. - Mxue Group's H1 2025 revenue reached 14.9 billion yuan, a 39% increase year-on-year, with net profit of 2.7 billion yuan, up 44%, driven by higher-than-expected store openings [2][8]. - Gu Ming's H1 2025 revenue was 5.7 billion yuan, a 41% year-on-year increase, with adjusted core profit of 1.1 billion yuan, up 49%, attributed to higher store count and single-store revenue [3][9]. Summary by Sections Ctrip - Q2 2025 revenue increased by 16% to 14.9 billion yuan, with accommodation booking revenue up 21%, transportation revenue up 11%, and group travel revenue up 5% [2][7]. - International OTA platform bookings grew over 60% year-on-year, with inbound tourism bookings more than doubling [2][7]. - The company has fully utilized its $400 million share buyback authorization and approved a new buyback plan of up to $5 billion [2][7]. Mxue Group - H1 2025 revenue was 14.9 billion yuan, a 39% increase, with net profit of 2.7 billion yuan, up 44% [2][8]. - The company is expanding in Southeast Asia, with daily sales growth in Indonesia and Vietnam, and plans for new stores in the U.S. and Latin America [2][8]. - The Lucky Coffee brand complements Mxue's offerings, focusing on freshly ground coffee, enhancing supply chain advantages [2][8]. Gu Ming - H1 2025 revenue reached 5.7 billion yuan, a 41% increase, with adjusted core profit of 1.1 billion yuan, up 49% [3][9]. - The company added 1,265 new stores, bringing the total to 11,179, with a significant increase in stores in lower-tier cities [3][9]. - The average daily GMV per store grew by 21% to 7,600 yuan, benefiting from substantial takeout subsidies [3][9]. Domestic Pharmaceutical Companies - Xinda Biologics reported H1 2025 revenue of 5.953 billion yuan, a 50.6% increase, with net profit turning positive at 834 million yuan [4][13]. - Kangfang Biologics achieved H1 2025 revenue of 1.472 billion yuan, a 37.8% increase, but reported a net loss of 588 million yuan [4][13]. - Rongchang Biologics reported H1 2025 revenue of 1.092 billion yuan, a 47.6% increase, with a reduced net loss of 450 million yuan [4][13]. Overseas Pharmaceutical Companies - Eli Lilly's GLP-1 obesity drug trial showed significant weight loss results, with the 36mg group achieving a 10.5% average weight reduction [5][16]. - BioArctic partnered with Novartis to develop a new CNS drug, receiving an upfront payment of $30 million [5][16]. - Regeneron announced positive results for its MG drug in a Phase III trial, achieving key endpoints [5][16].

Group 1 - The Hong Kong Innovative Drug ETF (159567) closed with a gain of 3.62% on August 29, with a trading volume of 2.004 billion yuan [1] - The fund was established on January 3, 2024, with an annual management fee of 0.50% and a custody fee of 0.10% [1] - As of August 28, 2024, the fund's latest share count was 6.619 billion, with a total size of 6.126 billion yuan, reflecting an increase of 1574.08% in shares and 1521.35% in size year-to-date [1] Group 2 - The current fund manager is Ma Jun, who has managed the fund since its inception, achieving a return of 85.10% during the tenure [2] - The top holdings of the fund include Innovent Biologics, WuXi Biologics, BeiGene, and others, with significant weightings such as 9.52% for Innovent Biologics and 9.47% for WuXi Biologics [2] - The fund's recent trading activity shows a cumulative trading amount of 34.226 billion yuan over the last 20 trading days, averaging 1.711 billion yuan per day [1]

Summary of Key Points Core Viewpoint - The Hong Kong stock market saw significant net inflows from Northbound trading, with a total net buy of 120.46 billion HKD on August 29, 2023, indicating strong investor interest in certain stocks, particularly Tencent and Alibaba [1]. Group 1: Northbound Trading Activity - Northbound trading recorded a net buy of 120.46 billion HKD, with 13.42 billion HKD from the Shanghai Stock Connect and 107.04 billion HKD from the Shenzhen Stock Connect [1]. - The most bought stocks included Tencent (00700), Alibaba-W (09988), and Innovent Biologics (01801) [1]. - The most sold stocks were Xiaomi Group-W (01810), New China Life Insurance (01336), and SMIC (00981) [1]. Group 2: Individual Stock Performance - Tencent (00700) had a net buy of 15.83 billion HKD, supported by strong performance from its mobile game "Valorant," with projected first-year revenue of 5 to 6 billion RMB [4]. - Alibaba-W (09988) saw a net buy of 11.49 billion HKD, reporting Q1 FY2026 revenue of 247.65 billion RMB, a 2% year-on-year increase, and a record high capital expenditure of 38.68 billion RMB, up 220% [5]. - Innovent Biologics (01801) received a net buy of 7.18 billion HKD, with a 50.6% increase in revenue to approximately 6 billion RMB in the first half of the year, exceeding market expectations [5]. Group 3: Notable Net Sales - Xiaomi Group-W (01810) faced a net sell of 8.61 billion HKD, with a 40% year-on-year increase in automotive revenue, but smartphone business margins were under pressure due to rising storage costs [7]. - New China Life Insurance (01336) experienced a net sell of 3.34 billion HKD, despite reporting a 25.5% increase in revenue to 69.43 billion RMB and a 33.5% increase in net profit [7]. - SMIC (00981) had a net sell of 614.7 million HKD, reflecting ongoing challenges in the semiconductor sector [7].

Group 1 - The core viewpoint of the report is that Kangfang Biotech (09926) achieved a revenue of 1.41 billion RMB in the first half of the year, representing a year-on-year growth of 38% [1] - The sales of pharmaceuticals amounted to 1.4 billion RMB, with a year-on-year increase of 49%, primarily due to the inclusion of Cadonilimab and Ivosidenib in the national medical insurance catalog [1] - The target price for Kangfang Biotech has been raised to 185 HKD, with a reiterated "buy" rating [1] Group 2 - The report highlights the expansion of indications for AK104 and AK112, particularly AK112, which is currently being tested in five Phase III clinical trials for cold tumors [1] - The peak sales forecast for AK104 and AK112 in China has been increased to 4.5 billion RMB and 8 billion RMB, respectively [1] - The overseas risk-adjusted peak sales forecast for AK112 has been raised to 7 billion USD [1]